共 41 条
- [41] The Guard1 clinical trial - A first in-human, phase 1/2 study evaluating AVR-RD-02, a hematopoietic stem cell (HSC) gene therapy for Gaucher disease: Preliminary safety, pharmacodynamic and clinical efficacy results from the subjects observed for up to 24 months post-infusion MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 3 - 4